MX381429B - Tricostatina a (tsa) para usarse en el tratamiento del cáncer. - Google Patents
Tricostatina a (tsa) para usarse en el tratamiento del cáncer.Info
- Publication number
- MX381429B MX381429B MX2016002307A MX2016002307A MX381429B MX 381429 B MX381429 B MX 381429B MX 2016002307 A MX2016002307 A MX 2016002307A MX 2016002307 A MX2016002307 A MX 2016002307A MX 381429 B MX381429 B MX 381429B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- trichostatin
- tsa
- treatment
- individual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361869039P | 2013-08-22 | 2013-08-22 | |
| PCT/US2014/052209 WO2015027121A2 (en) | 2013-08-22 | 2014-08-22 | Cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016002307A MX2016002307A (es) | 2016-06-15 |
| MX381429B true MX381429B (es) | 2025-03-12 |
Family
ID=51794948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016002307A MX381429B (es) | 2013-08-22 | 2014-08-22 | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20160199323A1 (https=) |
| EP (2) | EP3616754A1 (https=) |
| JP (4) | JP2016528297A (https=) |
| KR (5) | KR20170126018A (https=) |
| CN (2) | CN105579101A (https=) |
| AU (4) | AU2014308700A1 (https=) |
| CA (1) | CA2921036A1 (https=) |
| CL (1) | CL2016000397A1 (https=) |
| EA (1) | EA037667B1 (https=) |
| ES (1) | ES2755983T3 (https=) |
| MX (1) | MX381429B (https=) |
| WO (1) | WO2015027121A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210021602A (ko) * | 2013-08-22 | 2021-02-26 | 반다 파마슈티칼즈, 인코퍼레이티드. | 다발성 골수종 치료 |
| EP3616754A1 (en) * | 2013-08-22 | 2020-03-04 | Vanda Pharmaceuticals Inc. | Cancer treatment |
| WO2021016203A1 (en) * | 2019-07-19 | 2021-01-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Pdlim2 as a biomarker for cancer and as an anti-cancer treatment target |
| WO2023168201A1 (en) * | 2022-03-01 | 2023-09-07 | Vanda Pharmaceuticals Inc. | Trichostatin a (tsa) sensitivity in the treatment of tumors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4218478A (en) * | 1979-01-05 | 1980-08-19 | Ruiko Oiwa | Trichostatin as an antiprotozoal agent |
| CA1265431A (en) | 1985-01-08 | 1990-02-06 | Roderick John Macdonald | Electrode device for flare stack ignitor |
| JPS61176523A (ja) | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
| US20020183388A1 (en) | 2001-02-01 | 2002-12-05 | Gudas Lorraine J. | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors |
| SI2238982T1 (sl) * | 2003-06-27 | 2013-01-31 | Astellas Pharma Inc. | Terapevtsko sredstvo za mehkotkivni sarkom |
| CA2567350C (en) | 2004-05-21 | 2018-06-12 | John D. Shaughnessy | Use of gene expression profiling to predict survival in cancer patient |
| GB0519405D0 (en) | 2005-09-23 | 2005-11-02 | Univ Aberdeen | Cancer therapy prognosis and target |
| WO2007067516A2 (en) * | 2005-12-06 | 2007-06-14 | Duke University | Multiple myeloma |
| CA2652888A1 (en) | 2006-05-26 | 2007-12-06 | Celgene Corporation | Methods and compositions using immunomodulatory compounds in combination therapy |
| CA2574531C (en) * | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| US20110301055A1 (en) | 2008-12-05 | 2011-12-08 | Nicholas James Dickens | Methods for determining a prognosis in multiple myeloma |
| US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| WO2013071247A1 (en) * | 2011-11-10 | 2013-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Gene expression signatures of neoplasm responsiveness to theraphy |
| EP2602330A1 (en) | 2011-12-07 | 2013-06-12 | Palacky University, Olomouc | Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance |
| KR20210033067A (ko) * | 2012-06-04 | 2021-03-25 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| EP3616754A1 (en) * | 2013-08-22 | 2020-03-04 | Vanda Pharmaceuticals Inc. | Cancer treatment |
| KR20210021602A (ko) | 2013-08-22 | 2021-02-26 | 반다 파마슈티칼즈, 인코퍼레이티드. | 다발성 골수종 치료 |
| DE102014117278A1 (de) | 2014-11-25 | 2016-05-25 | Krones Ag | Hubeinheit zum Anheben und Absenken eines Behälters in einer Behälterbehandlungsanlage |
-
2014
- 2014-08-22 EP EP19201777.0A patent/EP3616754A1/en active Pending
- 2014-08-22 CN CN201480046624.5A patent/CN105579101A/zh active Pending
- 2014-08-22 KR KR1020177032020A patent/KR20170126018A/ko not_active Ceased
- 2014-08-22 KR KR1020217002758A patent/KR102315528B1/ko active Active
- 2014-08-22 KR KR1020167004630A patent/KR20160033779A/ko not_active Ceased
- 2014-08-22 EP EP14789436.4A patent/EP3036007B1/en active Active
- 2014-08-22 CN CN201910836673.3A patent/CN110585184A/zh active Pending
- 2014-08-22 JP JP2016536469A patent/JP2016528297A/ja active Pending
- 2014-08-22 KR KR1020237010047A patent/KR20230047203A/ko not_active Abandoned
- 2014-08-22 WO PCT/US2014/052209 patent/WO2015027121A2/en not_active Ceased
- 2014-08-22 AU AU2014308700A patent/AU2014308700A1/en not_active Abandoned
- 2014-08-22 MX MX2016002307A patent/MX381429B/es unknown
- 2014-08-22 KR KR1020217033186A patent/KR20210127821A/ko not_active Ceased
- 2014-08-22 EA EA201690445A patent/EA037667B1/ru unknown
- 2014-08-22 US US14/912,077 patent/US20160199323A1/en not_active Abandoned
- 2014-08-22 CA CA2921036A patent/CA2921036A1/en active Pending
- 2014-08-22 ES ES14789436T patent/ES2755983T3/es active Active
-
2016
- 2016-02-22 CL CL2016000397A patent/CL2016000397A1/es unknown
-
2018
- 2018-05-15 US US15/980,644 patent/US10265282B2/en active Active
-
2019
- 2019-03-18 US US16/357,249 patent/US11078289B2/en active Active
- 2019-05-08 JP JP2019088425A patent/JP2019167351A/ja active Pending
- 2019-11-06 AU AU2019261718A patent/AU2019261718A1/en not_active Abandoned
-
2021
- 2021-03-16 JP JP2021042699A patent/JP2021105005A/ja active Pending
- 2021-06-28 US US17/359,986 patent/US11667718B2/en active Active
- 2021-11-03 AU AU2021261882A patent/AU2021261882B2/en active Active
-
2022
- 2022-03-30 AU AU2022202183A patent/AU2022202183B2/en active Active
-
2023
- 2023-03-22 JP JP2023045826A patent/JP2023088996A/ja active Pending
- 2023-04-25 US US18/306,601 patent/US12590162B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502075B1 (en) | Treatment of cataplexy | |
| ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
| MX2016000271A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| MX370664B (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
| EA201890411A1 (ru) | Терапевтически активные соединения и способы их применения | |
| MX384909B (es) | Un anticuerpo anti-tau para usarse al tratar una tauopatía. | |
| PH12016500164B1 (en) | Therapeutically active compounds and their methods of use | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| CR20160308A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| EA201790312A1 (ru) | Комбинации лекарственных средств для лечения множественной миеломы | |
| MX365321B (es) | Métodos para el tratamiento de neutropenia mediante agonistas retinoides. | |
| MX380689B (es) | Tratamiento de cancer con dihidropirazino-pirazinas. | |
| UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
| MX381102B (es) | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. | |
| MX2017000306A (es) | Metodos para tratar hipotension. | |
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
| AR102871A1 (es) | Métodos de tratamiento de fibrosis | |
| MX381429B (es) | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. | |
| CL2018001719A1 (es) | Tratamiento contra el mieloma múltiple (divisional solicitud 201600396) | |
| BR112016012248A2 (pt) | método de tratamento de nefropatia | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| EA201690914A1 (ru) | Новое соединение для лечения тяжелой гипогликемии |